Multiple myeloma is fatal primarily because cancerous plasma cells crowd out healthy blood cell production, destroy bone, and damage organs. Most deaths result from infections the body can no longer fight, kidney failure caused by toxic proteins, or complications from dangerously high calcium levels. Understanding these pathways can help you make sense of what happens as the disease progresses and why certain symptoms matter.
How Myeloma Weakens the Immune System
Infection is the leading cause of death in multiple myeloma, and the reason traces back to what the cancer actually is. Myeloma is a cancer of plasma cells, the white blood cells responsible for producing antibodies. When these cells become malignant, they multiply uncontrollably in the bone marrow and churn out enormous quantities of a single, useless antibody protein. Meanwhile, the production of normal, functional antibodies drops sharply.
This creates a condition called secondary antibody deficiency: your blood contains high levels of one abnormal protein but dangerously low levels of the diverse antibodies you need to fight bacteria, viruses, and fungi. The expanding tumor cells also interfere with other immune defenders, including neutrophils (the first responders to bacterial infections) and dendritic cells (which help coordinate immune attacks). The result is an immune system with multiple blind spots.
Pneumonia and bloodstream infections (sepsis) are particularly dangerous in this setting. A lung infection that a healthy immune system would contain can spiral into respiratory failure. Sepsis can cause organ shutdown within hours. These infections become more frequent and harder to treat as the disease advances, especially in patients whose immune systems have been further suppressed by chemotherapy or stem cell transplants.
Kidney Failure From Toxic Proteins
About 20 to 50 percent of myeloma patients develop significant kidney problems, and for some, kidney failure is ultimately what ends their life. The mechanism is specific to this cancer. Myeloma cells produce not only whole antibody proteins but also smaller protein fragments called free light chains. These fragments are filtered through the kidneys, and in large quantities, they cause direct damage.
In the kidney’s filtering tubes, these light chains interact with a natural protein called uromodulin to form solid casts that physically block urine flow. This obstruction triggers a chain reaction: the filtering rate drops suddenly, tubules can rupture, and severe inflammation sets in. If the blockage isn’t reversed quickly, it leads to permanent scarring of kidney tissue. At the same time, the kidney’s upper filtering tubes absorb massive amounts of these toxic light chains, which triggers oxidative stress and inflammatory signaling that compounds the damage.
Once the kidneys fail beyond recovery, dialysis becomes necessary to survive. But dialysis in a patient with advancing cancer, ongoing infections, and bone disease carries its own serious risks. Kidney failure also limits which myeloma treatments can be safely given, creating a difficult cycle where the organ damage restricts the ability to treat the cancer causing it.
Bone Destruction and Dangerous Calcium Levels
Myeloma cells don’t just live in the bone marrow. They actively break down bone tissue around them. This destruction releases calcium into the bloodstream, sometimes pushing levels to life-threatening heights. Normal corrected serum calcium sits below about 2.6 mmol/L. Myeloma patients in crisis can reach levels above 4.0 mmol/L, more than 50 percent higher than normal.
Mild hypercalcemia causes confusion, fatigue, and nausea. At extreme levels, calcium disrupts the electrical signals that keep the heart beating in rhythm. Case reports document myeloma patients developing irregular heart rhythms including episodes where the heart briefly stops (sinus arrest), abnormally fast rhythms, and conduction blocks where electrical signals between the upper and lower chambers of the heart slow or fail. Severe hypercalcemia can also cause neurological collapse, with patients becoming unresponsive before cardiac arrest occurs.
Bone destruction also causes pathologic fractures, where bones break from minimal force or even body weight alone. Spinal fractures can compress the spinal cord, leading to paralysis. While fractures themselves are rarely the direct cause of death, they contribute to immobility, blood clots, and a declining ability to tolerate further treatment.
Blood Thickening and Vascular Complications
The massive quantity of abnormal protein circulating in the blood can thicken it significantly, a condition called hyperviscosity syndrome. Thicker blood flows more slowly through small vessels, reducing oxygen delivery to tissues. The brain is especially vulnerable: sluggish blood flow through tiny cerebral vessels can cause stroke-like symptoms or actual strokes. Patients may experience blurred vision, headaches, confusion, or sudden neurological deficits.
The excess proteins also interfere with platelet function, impairing the blood’s ability to clot properly. This creates a paradox where myeloma patients face both an increased risk of blood clots from sluggish circulation and an increased risk of dangerous bleeding from impaired clotting. Either complication can be fatal, particularly in patients already weakened by other effects of the disease.
When Treatment Itself Causes Harm
Myeloma treatments, while often effective at controlling the disease for years, carry their own mortality risks. One of the most serious is the development of a second cancer. Myeloma patients who develop a treatment-related blood cancer such as acute myeloid leukemia or a pre-leukemic condition called myelodysplastic syndrome face a 8.5 times higher risk of death compared to myeloma patients without a second cancer. The prognosis is grim: median survival after developing one of these secondary blood cancers is just 2.4 months, with only about 16 percent of patients surviving one year.
Overall, myeloma patients who develop any type of second malignancy have a 2.3 times higher risk of death than those who don’t. These secondary cancers are relatively uncommon, but they represent a real trade-off of long-term treatment. Chemotherapy and certain maintenance drugs can damage the DNA of healthy bone marrow cells, occasionally transforming them into a new and aggressive cancer years after the original myeloma treatment began.
How These Causes Overlap
In practice, myeloma deaths rarely result from a single clean cause. A patient with advancing disease might have moderately impaired kidneys, a weakened immune system, and thinning bones simultaneously. An infection that a healthier body could survive becomes fatal when the kidneys can’t handle the stress of sepsis and the immune system can’t mount an adequate response. High calcium from worsening bone disease compounds kidney damage, which limits treatment options, which allows the cancer to progress further.
Mortality rates are highest in patients over 90, and men die from myeloma more often than women. The disease remains incurable for most patients, though modern treatments have extended median survival significantly compared to previous decades. For many patients, the eventual cause of death involves this accumulation of overlapping organ damage rather than a single catastrophic event, which is why the trajectory often involves a gradual decline punctuated by acute crises like infections or fractures that the body can no longer recover from.